
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics demonstrates strong potential as a clinical-stage biotechnology company, with early clinical data indicating significant improvements in regulatory T cell (Treg) function and biomarkers related to neurodegenerative diseases. The company's fiscal year 2025 showed a marked increase in collaboration revenue, rising to $7.9 million, primarily due to the successful acceptance of the Investigational New Drug (IND) application for COYA 302 in ALS, marking a decisive shift towards clinical execution. Additionally, ongoing advancements in clinical trials, including statistically significant results in Treg metrics, put Coya Therapeutics in a favorable position to provide ongoing updates that may reduce risks associated with its lead assets, bolstering investor confidence in its therapeutic pipeline.
Bears say
Coya Therapeutics Inc. reported a net loss of $21.2 million in 2025, an increase from $14.9 million in 2024, indicating worsening financial performance and rising operational costs. The company's key intellectual property may fail to adequately protect its products, posing a significant risk to its competitive positioning in the market. Additionally, potential patent interference proceedings and the evolving landscape of treatment methods for neurodegenerative, autoimmune, and metabolic diseases could further threaten the viability of Coya's therapies and contribute to future legal expenses.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares